CL2023001791A1 - Formas solidas de un inhibidor de eif4e - Google Patents
Formas solidas de un inhibidor de eif4eInfo
- Publication number
- CL2023001791A1 CL2023001791A1 CL2023001791A CL2023001791A CL2023001791A1 CL 2023001791 A1 CL2023001791 A1 CL 2023001791A1 CL 2023001791 A CL2023001791 A CL 2023001791A CL 2023001791 A CL2023001791 A CL 2023001791A CL 2023001791 A1 CL2023001791 A1 CL 2023001791A1
- Authority
- CL
- Chile
- Prior art keywords
- solid forms
- eif4e inhibitor
- methyl
- pharmaceutical compositions
- eif4e
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 101150114135 eIF4E gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a formas sólidas de 7-(5-cloro-2-(3-(5-ciano-6-(1-(3,3-difluorociclobutil) piperidin-4-il) (metil) amino)-2-metil-4-oxopirido [3,4-d] pirimidin -3 (4H)-il) prop-1-in-1-il) fenil)-N-(metilsulfonil) tieno [3 2-b] piridin-3-carboxamida, a composiciones farmacéuticas que comprenden tales formas sólidas, y a métodos para usar tales formas sólidas y composiciones farmacéuticas para el tratamiento de cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129170P | 2020-12-22 | 2020-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001791A1 true CL2023001791A1 (es) | 2023-11-17 |
Family
ID=79288103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001791A CL2023001791A1 (es) | 2020-12-22 | 2023-06-16 | Formas solidas de un inhibidor de eif4e |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240076301A1 (es) |
| EP (1) | EP4267586A1 (es) |
| JP (1) | JP2023554521A (es) |
| KR (1) | KR20230124648A (es) |
| CN (1) | CN117337293A (es) |
| AU (1) | AU2021405409A1 (es) |
| CA (1) | CA3206158A1 (es) |
| CL (1) | CL2023001791A1 (es) |
| IL (1) | IL303932A (es) |
| WO (1) | WO2022137174A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202428278A (zh) * | 2022-12-23 | 2024-07-16 | 大陸商南京聖和藥業股份有限公司 | 作為ｅＩＦ４Ｅ抑制劑的化合物及其應用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| WO2014179237A1 (en) * | 2013-04-29 | 2014-11-06 | Vanderbilt University | Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 |
| TWI748541B (zh) | 2019-07-02 | 2021-12-01 | 美商ｅＦＦＥＣＴＯＲ醫療公司 | ｅＩＦ４Ｅ抑制性化合物與方法 |
-
2021
- 2021-12-22 AU AU2021405409A patent/AU2021405409A1/en active Pending
- 2021-12-22 WO PCT/IB2021/062202 patent/WO2022137174A1/en active Application Filing
- 2021-12-22 JP JP2023537984A patent/JP2023554521A/ja active Pending
- 2021-12-22 EP EP21840150.3A patent/EP4267586A1/en active Pending
- 2021-12-22 KR KR1020237024635A patent/KR20230124648A/ko unknown
- 2021-12-22 CN CN202180093844.3A patent/CN117337293A/zh active Pending
- 2021-12-22 CA CA3206158A patent/CA3206158A1/en active Pending
- 2021-12-22 US US18/268,795 patent/US20240076301A1/en active Pending
- 2021-12-22 IL IL303932A patent/IL303932A/en unknown
-
2023
- 2023-06-16 CL CL2023001791A patent/CL2023001791A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023554521A (ja) | 2023-12-27 |
| CA3206158A1 (en) | 2022-06-30 |
| AU2021405409A1 (en) | 2023-07-06 |
| CN117337293A (zh) | 2024-01-02 |
| WO2022137174A1 (en) | 2022-06-30 |
| KR20230124648A (ko) | 2023-08-25 |
| US20240076301A1 (en) | 2024-03-07 |
| AU2021405409A9 (en) | 2024-05-30 |
| EP4267586A1 (en) | 2023-11-01 |
| IL303932A (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202303227B (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| ECSP22083904A (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| CL2023001791A1 (es) | Formas solidas de un inhibidor de eif4e | |
| PE20191499A1 (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
| AR063097A1 (es) | Pirazolopirimidinas[1,5-a] inhibidoras de quinasas dependientes de ciclina(cdk), composiciones farmaceuticas que las contienen y usos en el tratamiento de enfermedades proliferativas | |
| ECSP066763A (es) | Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes | |
| AR056347A1 (es) | Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas | |
| ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
| EA201290149A1 (ru) | Комбинация | |
| CL2011001378A1 (es) | Compuestos derivados de pirimidin oxi-indoles, inhibidores de vegf-r2; composicion farmaceutica que los comprende; uso en el tratamiento de una enfermedad o trastorno proliferativo tales como enfermedades tumorales y enfermedades de neovascularizacion ocular. | |
| AR107751A1 (es) | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton | |
| MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
| CL2008003575A1 (es) | Compuestos derivados de 1,5-dihidropirazolo[3,4-d]piridin-4-ona, inhibidores de pde9a; composicion farmaceutica que los comprende; y su uso en el tratamiento y prevencion del alzheimer, parkinson, esclerosis multiple, demencia vascular, esquizofrenia con demencia, entre otras. | |
| ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
| ECSP088906A (es) | PIRAZOLO 1,5-a PIRIMIDINAS | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| ECSP109937A (es) | Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt. | |
| CR10601A (es) | Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt | |
| ECSP099525A (es) | Inhibidores de mek | |
| UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| BRPI0606322A2 (pt) | formulações intravenosas de inibidores de pde-5 | |
| ECSP11005642A (es) | Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas | |
| CL2022000995A1 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y segundos principios activos para uso combinado | |
| BR112022023937A2 (pt) | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |